Menus Subscribe Search

Follow us

Genes Are Us


Elizabeth Taylor in Cleopatra. (Photo: Wikimedia Commons)

Elizabeth Taylor, My Great-Grandpa, and the Future of Antibiotics

• June 27, 2014 • 4:00 AM

Elizabeth Taylor in Cleopatra. (Photo: Wikimedia Commons)

While it’s not clear whether or not they worked for the Cleopatra star over a half-century ago, phage treatments could help solve the growing problem of antibiotic resistance.

In March of 1961, Elizabeth Taylor was in London filming her next blockbuster, Cleopatra, when she fell ill with pneumonia. She underwent an emergency tracheotomy, and for days the press followed every development in her increasingly dire situation. On March 7, a Philadelphia-area newspaper reported that a local company, Delmont Laboratories, had put several doses of an unusual antibacterial treatment on the next jet to London at the request of Taylor’s doctors. With a touch of community pride, the paper reported that the treatment, “staphylococcus bacteriophage lysate,” was exclusively manufactured by Delmont Laboratories, and that “Christopher Roos, laboratory director and formerly senior bacteriologist for Sharpe and Dohme, played a major part in its development.”

It’s not clear what impact the treatment had on Elizabeth Taylor, but Christopher Roos, my great-grandfather, didn’t doubt its efficacy. My mother recalls that during her childhood visits to his house, he would treat her colds with a dose, administered as a nasal spray. Staphylococcus bacteriophage lysate is a form of antibacterial therapy based on phages, viruses that are the natural predators of bacteria. Discovered early in the 20th century, decades before modern antibiotics, phages have an obvious therapeutic potential that doctors and scientists were quick to explore. In the 1930s and ’40s, bacteriophage preparations were manufactured by major drug companies like Eli Lilly, and used to treat everything from cholera to wound infections.

Aside from the technological advances, there is now a major medical and economic reason to reconsider phages: the growing crisis of antibiotic resistance. The number of antibiotic-resistant bacterial infections is growing rapidly, while the drug pipeline of new antibiotics is drying up.

But the hype got a bit ahead of the science. The biology of these viruses was not well understood, and phage treatments were difficult to prepare consistently. The effectiveness of the treatments varied widely, and while there were some clinical studies of phage therapy, many weren’t particularly rigorous by rapidly modernizing, post-World War II standards. In the mid-1940s, penicillin, cheap and obviously effective, began to be mass-produced in the U.S. By the time that Liz Taylor’s doctors called my great-grandfather, phage therapy was on the wane. Knowing that, the story sounds like the familiar scenario of the celebrity doctor who peddles some unproven alternative treatment to his famous patient.

But that characterization isn’t accurate. Despite the lack of rigor in the early studies, there is a long record of substantial evidence showing that phage therapy holds genuine promise. After phage therapy was superseded by antibiotics in the West, researchers in the Soviet Union and Eastern Europe—where antibiotics weren’t as readily available—continued to work on phage therapy, with encouraging results. Some occasional studies continued in the U.S. and Western Europe as well. And now, phage therapy is in the limelight again, drawing the interest of researchers, governments, and biotech companies.

What changed? As my Washington University colleague Jeffrey Gordon and his co-workers wrote, we’re experiencing “the incipient rise of a phage biology renaissance,” thanks to modern DNA analysis technologies. Discovered before we knew that genes were made of DNA, we now know that phages are highly efficient gene-delivery machines. They inject their genomes into bacteria, hijack the bacterial machinery to make new DNA copies of themselves, and repackage those copies into protein capsules, bursting open the bacterial cell in the process. The capsules then diffuse away in search of new bacterial prey. By scouring oceans, soil, and our own bodies for phage DNA, researchers have discovered an enormous world of viruses with a tremendous bacterial-killing capability—according to one review, “phage predation destroys an estimated half of the world bacteria population every 48 hours.” The diversity of the world’s bacteriophages is an essentially inexhaustible source that we can trawl for potential anti-bacterial treatments, with the aid of today’s highly effective biotechnological tools. And researchers like Gordon and his lab members are exploring how phages operate in their natural habitats, such as the human gut.

Aside from the technological advances, there is now a major medical and economic reason to reconsider phages: the growing crisis of antibiotic resistance. As the Centers for Disease Control reported last year, the number of antibiotic-resistant bacterial infections is growing rapidly, while the drug pipeline of new antibiotics is drying up. Two million people acquire antibiotic-resistant infections each year in the U.S., leading to over $20 billion in health care costs. And antibiotics themselves pose a major burden, accounting for 20 percent of all emergency room visits for adverse drug events.

Phage therapy has the potential to avoid all of these problems. While bacteria can become resistant to any one strain of phage, there are many different phage strains out there that could be combined into an effective, multi-strain cocktail treatment. And unlike chemical antibiotics, phages have their own genomes that can evolve to circumvent the defenses of resistant bacteria. Phage therapy also would not destroy the important community of healthy bacteria in our guts. Antibiotics wipe out these healthy gut bacteria, leaving people vulnerable to opportunistic infections by Clostridium difficile, a bacteria that the CDC reports is responsible for 14,000 deaths each year in the U.S.

The need is there, but will phage therapy actually work in humans? The answer is a cautious yes. The biomedical research community is certainly ready to try, bringing new funding, technology, and rigor to this old-fashioned approach to infections. A clinical trial of phage therapy for infected burn wounds is underway in Europe. The FDA has already approved phages to kill contaminating bacteria in food, and phage treatments for infections are being tested for efficacy in some animal studies, as well as for safety in a few human studies (PDF). Phage therapy may or may not become the major solution to our crisis of antibiotic resistance, but it is very likely that we’ll soon see a variety of limited but successful applications of phage therapy in humans.

Delmont’s product was a federally-approved drug in the 1950s, but as the FDA revised its approach to regulation in later decades, the small company struggled (PDF), and, in the 1990s, it stopped selling its bacteriophage treatments for human use. The company continues to make a USDA-licensed phage therapy to treat recalcitrant skin infections in dogs. When my great-grandfather sent those doses of phage lysate express to Liz Taylor, the time wasn’t quite right for phage therapy, scientifically or economically. But times have changed, and this old-fashioned treatment may become cutting-edge.

Michael White
Michael White is a systems biologist at the Department of Genetics and the Center for Genome Sciences and Systems Biology at the Washington University School of Medicine in St. Louis, where he studies how DNA encodes information for gene regulation. He co-founded the online science pub The Finch and Pea. Follow him on Twitter @genologos.

More From Michael White

A weekly roundup of the best of Pacific Standard and, delivered straight to your inbox.

Recent Posts

October 31 • 4:00 PM

Should the Victims of the War on Drugs Receive Reparations?

A drug war Truth and Reconciliation Commission along the lines of post-apartheid South Africa is a radical idea proposed by the Green Party. asks their candidates for New York State’s gubernatorial election to tell us more.

October 31 • 2:00 PM

India’s Struggle to Get Reliable Power to Hundreds of Millions of People

India’s new Prime Minister Narendra Modi is known as a “big thinker” when it comes to energy. But in his country’s case, could thinking big be a huge mistake?

October 31 • 12:00 PM

In the Picture: SNAP Food Benefits, Birthday Cake, and Walmart

In every issue, we fix our gaze on an everyday photograph and chase down facts about details in the frame.

October 31 • 10:15 AM

Levels of Depression Could Be Evaluated Through Measurements of Acoustic Speech

Engineers find tell-tale signs in speech patterns of the depressed.

October 31 • 8:00 AM

Who Wants a Cute Congressman?

You probably do—even if you won’t admit it. In politics, looks aren’t everything, but they’re definitely something.

October 31 • 7:00 AM

Why Scientists Make Promises They Can’t Keep

A research proposal that is totally upfront about the uncertainty of the scientific process and its potential benefits might never pass governmental muster.

October 31 • 6:12 AM

The Psychology of a Horror Movie Fan

Scientists have tried to figure out the appeal of axe murderers and creepy dolls, but it mostly remains a spooky mystery.

October 31 • 4:00 AM

The Power of Third Person Plural on Support for Public Policies

Researchers find citizens react differently to policy proposals when they’re framed as impacting “people,” as opposed to “you.”

October 30 • 4:00 PM

I Should Have Told My High School Students About My Struggle With Drinking

As a teacher, my students confided in me about many harrowing aspects of their lives. I never crossed the line and shared my biggest problem with them—but now I wish I had.

October 30 • 2:00 PM

How Dark Money Got a Mining Company Everything It Wanted

An accidentally released court filing reveals how one company secretly gave money to a non-profit that helped get favorable mining legislation passed.

October 30 • 12:00 PM

The Halloween Industrial Complex

The scariest thing about Halloween might be just how seriously we take it. For this week’s holiday, Americans of all ages will spend more than $5 billion on disposable costumes and bite-size candy.

October 30 • 10:00 AM

Sky’s the Limit: The Case for Selling Air Rights

Lower taxes and debt, increased revenue for the city, and a much better use of space in already dense environments: Selling air rights and encouraging upward growth seem like no-brainers, but NIMBY resistance and philosophical barriers remain.

October 30 • 9:00 AM

Cycles of Fear and Bias in the Criminal Justice System

Exploring the psychological roots of racial disparity in U.S. prisons.

October 30 • 8:00 AM

How Do You Make a Living, Email Newsletter Writer?

Noah Davis talks to Wait But Why writer Tim Urban about the newsletter concept, the research process, and escaping “money-flushing toilet” status.

October 30 • 6:00 AM

Dreamers of the Carbon-Free Dream

Can California go full-renewable?

October 30 • 5:08 AM

We’re Not So Great at Rejecting Each Other

And it’s probably something we should work on.

October 30 • 4:00 AM

He’s Definitely a Liberal—Just Check Out His Brain Scan

New research finds political ideology can be easily determined by examining how one’s brain reacts to disgusting images.

October 29 • 4:00 PM

Should We Prosecute Climate Change Protesters Who Break the Law?

A conversation with Bristol County, Massachusetts, District Attorney Sam Sutter, who dropped steep charges against two climate change protesters.

October 29 • 2:23 PM

Innovation Geography: The Beginning of the End for Silicon Valley

Will a lack of affordable housing hinder the growth of creative start-ups?

October 29 • 2:00 PM

Trapped in the Tobacco Debt Trap

A refinance of Niagara County, New York’s tobacco bonds was good news—but for investors, not taxpayers.

October 29 • 12:00 PM

Purity and Self-Mutilation in Thailand

During the nine-day Phuket Vegetarian Festival, a group of chosen ones known as the mah song torture themselves in order to redirect bad luck and misfortune away from their communities and ensure a year of prosperity.

October 29 • 10:00 AM

Can Proposition 47 Solve California’s Problem With Mass Incarceration?

Reducing penalties for low-level felonies could be the next step in rolling back draconian sentencing laws and addressing the criminal justice system’s long legacy of racism.

October 29 • 9:00 AM

Chronic Fatigue Syndrome and the Brain

Neuroscientists find less—but potentially stronger—white matter in the brains of patients with CFS.

October 29 • 8:00 AM

America’s Bathrooms Are a Total Failure

No matter which American bathroom is crowned in this year’s America’s Best Restroom contest, it will still have a host of terrible flaws.

Follow us

Levels of Depression Could Be Evaluated Through Measurements of Acoustic Speech

Engineers find tell-tale signs in speech patterns of the depressed.

We’re Not So Great at Rejecting Each Other

And it's probably something we should work on.

Chronic Fatigue Syndrome and the Brain

Neuroscientists find less—but potentially stronger—white matter in the brains of patients with CFS.

Incumbents, Pray for Rain

Come next Tuesday, rain could push voters toward safer, more predictable candidates.

Could Economics Benefit From Computer Science Thinking?

Computational complexity could offer new insight into old ideas in biology and, yes, even the dismal science.

The Big One

One town, Champlain, New York, was the source of nearly half the scams targeting small businesses in the United States last year. November/December 2014

Copyright © 2014 by Pacific Standard and The Miller-McCune Center for Research, Media, and Public Policy. All Rights Reserved.